𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II clinical trial of 13-cis-retinoic acid and interferon-α-2a in patients with advanced esophageal carcinoma

✍ Scribed by Peter C. Enzinger; David H. Ilson; Leonard B. Saltz; Lisa K. Martin; David P. Kelsen

Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
68 KB
Volume
85
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

BACKGROUND.

Interferon in combination with 5-fluorouracil has been shown to be active in squamous cell carcinoma (SCC) and adenocarcinoma (AC) of the esophagus. 13-cis-retinoic acid (CRA) has chemopreventive activity in SCC of the head and neck, and, in combination with interferon, has antitumor activity in SCC of the skin and cervix.

METHODS.

The activity and toxicity of CRA and interferon-␣-2a (IFN) in patients with advanced esophageal carcinoma was evaluated in a Phase II single institution trial. Patients had unresectable or metastatic AC or SCC of the esophagus. One prior chemotherapy regimen was allowed. IFN was given by daily subcutaneous injection at a dose of 3 million U and CRA was taken orally at a dose of 1 mg/kg/day in 2 divided doses. Treatment was given in cycles of 4 weeks and continued until documented disease progression.

📜 SIMILAR VOLUMES

A Phase II pilot trial of 13-cis retinoi
A Phase II pilot trial of 13-cis retinoic acid and interferon-α in patients with advanced pancreatic carcinoma
✍ Felix H. Brembeck; Klaus Schoppmeyer; Ursula Leupold; Costel Gornistu; Volker Ke 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB

## BACKGROUND. Advanced unresectable pancreatic adenocarcinoma has a dismal prognosis. The authors previously have shown that retinoic acid (RA) and interferon-␣ (IFN-␣) inhibit growth and induce differentiation in human pancreatic carcinoma cells in vitro and in vivo. The purpose of this trial wa

Phase II clinical trial with 5-fluoroura
Phase II clinical trial with 5-fluorouracil, recombinant interferon-α-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus
✍ Scott Wadler; Hilda Haynes; Jonathan J. Beitler; Xiaoping Hu; Stanley Fell; Marg 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 393 KB

## Background: Recombinant interferon-alpha (ifn) augments the cytotoxicity of both 5-fluorouracil (5-fu) and cisplatin in vitro. a phase ii study of 5-fu and ifn resulted in response rates of 25-27% in patients with metastatic esophageal carcinoma. ## Methods: A phase ii trial was initiated to d

A phase II trial of interferon-α and 5-f
A phase II trial of interferon-α and 5-fluorouracil in patients with advanced renal cell carcinoma: A Southwest Oncology Group study
✍ Laurence Elias; Brent A. Blumenstein; Julie Kish; Robert C. Flanigan; James L. W 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB 👁 1 views

## BACKGROUND. Renal cell carcinoma is a common neoplasm that is often refractory to treatment. It is occasionally responsive to immunoniodulating agents including interferon-a, which enhances the effects of 5-fluorouracil upon cells. Combinations of these two drugs have been most frequently tested

All-trans retinoic acid and interferon-α
All-trans retinoic acid and interferon-α-2a in patients with metastatic or recurrent carcinoma of the uterine cervix : Clinical and pharmacokinetic studies
✍ Scott Wadler; Edward L. Schwartz; Hilda Haynes; Ronalde Rameau; Astrid Quish; Jo 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 1 views

## Background: Recent clinical trials with a combination of interferon (ifn alpha) and 13 cis-retinoic acid resulted in high response rates among women with locally advanced and metastatic carcinoma of the uterine cervix. the authors sought to amplify these observations by employing the isomer of 1